Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer

Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer

Oncolytic virotherapy is a promising therapeutic approach for the treatment of cancer. TG6002 is a recombinant oncolytic vaccinia virus deleted in the thymidine kinase and ribonucleotide reductase genes and armed with the suicide gene FCU1, which encodes a bifunctional chimeric protein that efficien...

Full description

Bibliographic Details
Main Authors: Jérémy Béguin, Johann Foloppe, Christelle Maurey, Eve Laloy, Julie Hortelano, Virginie Nourtier, Christelle Pichon, Sandrine Cochin, Pascale Cordier, Hélène Huet, Eric Quemeneur, Bernard Klonjkowski, Philippe Erbs
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Molecular Therapy: Oncolytics
Subjects:
oncolytic virotherapy
vaccinia virus
TG6002
FCU1
suicide gene therapy
mammary tumor
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770520301376

Internet

http://www.sciencedirect.com/science/article/pii/S2372770520301376

Similar Items